Could your own fat cells heal Crohn's fistulas? new trial tests it

NCT ID NCT04612465

Ongoing Disease control Sponsor: Anterogen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether injecting a patient's own fat-derived stem cells, along with a glue, can close fistulas caused by Crohn's disease. 46 adults with Crohn's and at least one fistula are taking part. The main goal is to see if the fistula closes completely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Autologous adipose-derived stem cells (a patient's own fat stem cells) combined with fibrin glue
What this could lead to: If it works, this could offer a new way to close hard-to-treat fistulas in Crohn's disease, potentially reducing the need for surgery or long-term medication.
What could go wrong: This is a small Phase 3 trial with only 46 people, so results may not apply to everyone. Stem cell treatments can have side effects like infection or inflammation, and the fistula might not fully close.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal fistula Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S FISTULA

Contacts and locations

Locations

Asan Medical Center

Seoul, Seoul, 05505, South Korea
Samsung Medical Center

Seoul, Seoul, 06351, South Korea
Seoul Natinoal Univetsity Hospital

Seoul, Seoul, 03080, South Korea
Severance

Seoul, Seodaemun-gu, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.